Saturday 16 March 2013

GENITAL HERPES FACTS


INTRODUCTION
The incidence of herpes, a sexually transmitted disease, varies across the world. Among pregnant women with herpes, nearly 75% can expect at least one flare‐up during their pregnancy. Transmission of the virus from mother to baby typically occurs by direct contact with the virus during birth. It is often recommended that a cesarean should be offered to women with active lesions to reduce the risk of transmission to the baby. In addition, several antiviral agents are available for use both for therapy and for preventing a flare‐up. These antiviral drugs include acyclovir, penciclovir, valacyclovir, and famciclovir. The review assessed whether antiviral drugs given to pregnant women with herpes before a recurrence might be effective in reducing transmission to the baby. Seven studies were identified involving 1249 women. Giving antiviral drugs reduces viral shedding and recurrences at labor and birth. They also reduced the use of cesarean, but there is no evidence of reduction in neonatal herpes. Women should also be informed that the risk of the baby getting herpes during birth is low.



FACTS TO KNOW ABOUT GENITAL HERPES
1. Most people with genital herpes do not know it.
About 16% of people aged 14-49 in the U.S. are infected with the herpes simplex virus-2 (HSV-2) that causes genital herpes, but as many as 81% of them had not received the diagnosis.

2. Genital herpes is very common, infecting at least 45 million people aged 12 and older in the United States.

3. About one in five women between the ages of 14 and 49 have genital herpes caused by HSV-2, while about one in nine men in that same age range are infected.

4. Genital herpes is caused by a virus, so antibiotics will not help resolve the infection. There is no cure for herpes, but treatment is available to reduce and prevent outbreaks and decrease the risk of transmission to a partner.

5. As with other sexually transmitted diseases, herpes can be spread by close contact or sexual activity. It is highly unlikely to be spread by a toilet seat or other objects.

6. Genital herpes can be transmitted even if the infected partner has no symptoms or visible signs or doesn’t know he or she is infected.

7. Washing the genital area doesn’t help prevent any sexually transmitted disease (STD), including genital herpes. The best way to prevent any STD is to abstain from sex or engage in sex only with someone you know is not infected. Condoms are not guaranteed to prevent infection, but research has shown that they provide some protection.
The estimated number of pregnant women infected with HSV-2 is 880,000. Most transmission to newborns occurs during vaginal delivery. If a woman had genital herpes before getting pregnant, her baby may be infected but the chance is very low -- less than 1%. However, the risk of infecting the baby is much higher (25% to 50%) when a woman is newly infected late in pregnancy.
 8. If you are pregnant and think you may be infected, tell your doctor right away. Women with genital herpes are examined carefully for any symptoms before giving birth. If sores or signs that an outbreak is coming are present at the time of delivery, the baby may be delivered by cesarean section (C-section).

9. To find out if you have genital herpes, a doctor can take a sample from a sore and test it in the laboratory. There is also a blood test that looks for antibodies to the virus that your immune system would have made. HSV-2 almost always infects the genitals, so if antibodies to HSV-2 are detected in your blood, you probably have genital herpes.
A blood test that shows antibodies to HSV-1 means you could have genital or oral herpes. That's because oral herpes, typically caused by HSV-1, can be spread to the genitals during oral sex.
 
10. When a person is first infected with the herpes virus, if symptoms occur they usually develop within the first two weeks of virus transmission. Symptoms can include fever and flu-like symptoms, genital itching, burning and discomfort, vaginal discharge, swollen lymph nodes, and a feeling of abdominal pressure.
 
11. The classic symptom of genital herpes is small fluid-filled blisters that break, forming painful sores that crust and heal. These may appear four to seven days after the initial virus transmission.
 
12. Genital herpes typically causes several outbreaks (four or five) within a year of the first outbreak, with fewer and less severe outbreaks over time.
 
13. Some commonly reported triggers for genital herpes outbreaks include stress, illness, surgery, vigorous sex, diet, and menstrual periods.
 
14. Once inside the body, HSV-2 travels to the nerve roots near the spinal cord and settles there permanently.
 
15. About half the people who have recurrent outbreaks of genital herpes feel an outbreak coming a few hours to a couple of days before it happens. They may feel tingling, burning, itching, numbness, tenderness, or pain where the blisters are going to appear. This is called the prodrome.
 

LYMPHATIC FILARIASIS (ELEPHANTIASIS)

Lymphatic filariasis

Fact sheet N°102
Updated March 2013


Key facts

  • Nearly 1.4 billion people in 73 countries worldwide are threatened by lymphatic filariasis, commonly known as elephantiasis.
  • Over 120 million people are currently infected, with about 40 million disfigured and incapacitated by the disease.
  • Lymphatic filariasis can result in an altered lymphatic system and the abnormal enlargement of body parts, causing pain and severe disability.
  • Acute episodes of local inflammation involving the skin, lymph nodes and lymphatic vessels often accompany chronic lymphoedema.
  • To interrupt transmission WHO recommends an annual mass drug administration of single doses of two medicines to all eligible people in endemic areas.

The disease

Lymphatic filariasis, commonly known as elephantiasis, is a neglected tropical disease. Infection occurs when filarial parasites are transmitted to humans through mosquitoes. When a mosquito with infective stage larvae bites a person, the parasites are deposited on the person's skin from where they enter the body. The larvae then migrate to the lymphatic vessels where they develop into adult worms in the human lymphatic system.
Infection is usually acquired in childhood, but the painful and profoundly disfiguring visible manifestations of the disease occur later in life. Whereas acute episodes of the disease cause temporary disability, lymphatic filariasis leads to permanent disability.
Currently, more than 1.4 billion people in 73 countries are at risk. Approximately 65% of those infected live in the WHO South-East Asia Region, 30% in the African Region, and the remainder in other tropical areas.
Lymphatic filariasis afflicts over 25 million men with genital disease and over 15 million people with lymphoedema. Since the prevalence and intensity of infection are linked to poverty, its elimination can contribute to achieving the United Nations Millennium Development Goals.

Cause and transmission

Lymphatic filariasis is caused by infection with nematodes (roundworms) of the family Filariodidea. There are three types of these thread-like filarial worms:
  • Wuchereria bancrofti, which is responsible for 90% of the cases
  • Brugia malayi, which causes most of the remainder of the cases
  • B. timori, which also causes the diseases.
Adult worms lodge in the lymphatic system and disrupt the immune system. They live for 6-8 years and, during their life time, produce millions of microfilariae (small larvae) that circulate in the blood.
Lymphatic filariasis is transmitted by different types of mosquitoes for example by the Culex mosquito, widespread across urban and semi-urban areas; Anopheles mainly in rural areas, and Aedes, mainly in endemic islands in the Pacific.


Symptoms

Lymphatic filariasis infection involves asymptomatic, acute, and chronic conditions. The majority of infections are asymptomatic, showing no external signs of infection. These asymptomatic infections still cause damage to the lymphatic system and the kidneys as well as alter the body's immune system.
Acute episodes of local inflammation involving skin, lymph nodes and lymphatic vessels often accompany the chronic lymphoedema or elephantiasis. Some of these episodes are caused by the body's immune response to the parasite. However most are the result of bacterial skin infection where normal defences have been partially lost due to underlying lymphatic damage.
When lymphatic filariasis develops into chronic conditions, it leads to lymphoedema (tissue swelling) or elephantiasis (skin/tissue thickening) of limbs and hydrocele (fluid accumulation). Involvement of breasts and genital organs is common.
Such body deformities lead to social stigma, as well as financial hardship from loss of income and increased medical expenses. The socioeconomic burdens of isolation and poverty are immense.

Treatment and prevention

The recommended regimen for treatment through mass drug administration (MDA) is a single dose of two medicines given together - albendazole (400 mg) plus either ivermectin (150-200 mcg/kg) in areas where onchocerciasis (river blindness) is also endemic or diethylcarbamazine citrate (DEC) (6 mg/kg) in areas where onchocerciasis is not endemic. These medicines clear microfilariae from the bloodstream.
Mosquito control is another measure that can be used to suppress transmission. Measures such as insecticide-treated nets or indoor residual spraying may help protect populations in endemic regions from infection.
Patients with chronic disabilities like elephantiasis, lymphoedema, or hydrocele are advised to maintain rigorous hygiene and take necessary precautions to prevent secondary infection and aggravation of the disease condition.

WHO's response

World Health Assembly Resolution 50.29 encourages Member States to eliminate lymphatic filariasis as a public-health problem.
In response, WHO launched its Global Programme to Eliminate Lymphatic Filariasis (GPELF) in 2000. The goal of the GPELF is to eliminate lymphatic filariasis as a public-health problem by 2020.
The strategy is based on two key components:
  • interrupting transmission through annual large-scale treatment programmes, known as mass drug administration, implemented to cover the entire at-risk population;
  • alleviating the suffering caused by lymphatic filariasis through morbidity management and disability prevention.
Mass drug administration (MDA)
To achieve interruption of transmission first the disease is mapped to know where to administer MDA then community-wide annual MDA of single doses of albendazole plus either diethylcarbamazine or ivermectin is implemented in endemic regions, treating the entire at-risk population.
MDA should be continued for 4-6 years to fully interrupt transmission of infection. By 2011, 59 endemic countries had completed mapping, and 53 countries had started implementing MDA. Of the 53 countries that had implemented MDA, 12 countries have moved to the post-MDA surveillance phase.
From 2000 to 2011, more than 3.9 billion treatments were delivered to a targeted population of about 950 million individuals in 53 countries, considerably reducing transmission in many places. Recent research data show that the transmission of lymphatic filariasis in at-risk populations has dropped by 43% since the beginning of the GPELF. The overall economic benefit of the programme during 2000-2007 is conservatively estimated at US$ 24 billion.
Morbidity management
Morbidity management and disability prevention are vital for public health improvement and should be fully integrated into the health system. The GPELF aims to provide access to a minimum package of care for every person with acute dermatolymphangioadenitis (ADLA)/acute attacks, lymphoedema/elephantiasis or hydrocele in all areas where lymphatic filariasis is endemic, thus alleviating suffering and promoting improvement in their quality of life.
Clinical severity of lymphoedema and acute inflammatory episodes can be improved using simple measures of hygiene, skin care, exercise, and elevation of affected limbs. Hydrocele (fluid accumulation) can be cured with surgery.


SOURCE: WHO